MULTIPLE MYELOMA KNOWLEDGE CENTER

How is Doxil administered?

Doxil® (doxorubicin HCl liposome injection, Janssen) is administered as an injection directly into the vein (intravenously, or IV). When Doxil is used along with Velcade® (bortezomib, Takeda Oncology) in the treatment of myeloma, the recommended dosing over each 28-day cycle is as follows:

  • Velcade is given at a dose of 1.3 mg/m2 intravenously or as an injection under the skin on days 1, 4, 8, and 11.
  • Doxil is given intravenously at a dose of 30 mg/m2 over a 1-hour infusion on day 4 after Velcade is given.

Although there is limited information available on use of Doxil in patients with myeloma with reduced liver (hepatic) function, it is recommended that patients with hepatic impairment receive a lower dose of Doxil.

How long is the treatment with Doxil?

The length of treatment with Doxil may differ from patient to patient and is based on how well the drug is working and if the side effects are manageable. In general, patients are treated for up to 8 cycles until their disease progresses or if they experience unacceptable toxicity.